(ROIV) – Hot FDA News
-
Roivant(ROIV) Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA Cream, 1%
-
Roivant Sciences (ROIV) Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
Back to ROIV Stock Lookup
